Blueprint Medicines (NASDAQ:BPMC)‘s stock had its “buy” rating restated by investment analysts at Cowen in a research report issued to clients and investors on Thursday.

Several other analysts have also recently weighed in on the company. Guggenheim initiated coverage on Blueprint Medicines in a report on Tuesday, September 18th. They set a “buy” rating and a $102.00 price target for the company. ValuEngine cut Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. BidaskClub cut Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Saturday, August 25th. Wedbush reaffirmed an “outperform” rating and issued a $101.00 price objective on shares of Blueprint Medicines in a report on Monday, October 8th. Finally, Leerink Swann initiated coverage on Blueprint Medicines in a report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 price objective for the company. Two analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $97.14.

NASDAQ:BPMC traded down $3.22 during mid-day trading on Thursday, hitting $52.96. 59,195 shares of the stock were exchanged, compared to its average volume of 406,110. The stock has a market cap of $2.62 billion, a P/E ratio of -13.51 and a beta of 1.46. The company has a current ratio of 10.05, a quick ratio of 10.05 and a debt-to-equity ratio of 0.03. Blueprint Medicines has a fifty-two week low of $54.50 and a fifty-two week high of $109.00.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.09). The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.87 million. Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. The business’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.96) earnings per share. As a group, sell-side analysts forecast that Blueprint Medicines will post -5.25 EPS for the current year.

In other news, insider Marion Dorsch sold 2,300 shares of the business’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $70.47, for a total transaction of $162,081.00. Following the completion of the transaction, the insider now owns 2,300 shares of the company’s stock, valued at approximately $162,081. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $63.49, for a total value of $1,269,800.00. Following the transaction, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,269,800. The disclosure for this sale can be found here. 3.15% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC raised its holdings in shares of Blueprint Medicines by 46.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 28,317 shares of the biotechnology company’s stock worth $2,210,000 after buying an additional 8,949 shares in the last quarter. Pacer Advisors Inc. acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $286,000. BlueMountain Capital Management LLC acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $140,000. LPL Financial LLC acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $411,000. Finally, Algert Global LLC acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $447,000. 99.82% of the stock is owned by institutional investors.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Recommended Story: How are the companies in the S&P 500 selected?

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.